title: Bis(alpha-furancarboxylato)oxovanadium(IV) prevents and improves dexamethasone-induced insulin resistance in 3T3-L1 adipocytes.
abstract: Previous studies showed that bis(alpha-furancarboxylato)oxovanadium(IV) (BFOV), an orally active anti-diabetic organic vanadium complex, could improve insulin resistance in animals with type 2 diabetes. The present study has been carried out to evaluate the effects of BFOV on insulin-resistant glucose metabolism using dexamethasone-treated 3T3-L1 adipocytes as an in-vitro model of insulin resistance. The results showed that BFOV, similar to vanadyl sulfate and rosiglitazone, caused a concentration-dependent increase in glucose consumption by insulin-resistant adipocytes. Moreover, BFOV enhanced the action of insulin and completely prevented the development of insulin resistance induced by dexamethasone, leading to glucose consumption equal to that by normal cells. In addition, dexamethasone reduced the mRNA expression of insulin receptor substrate 1 (IRS-1) and glucose transporter 4 (GLUT4) in 3T3-L1 adipocytes, while BFOV normalized the expression of IRS-1 and GLUT4. These findings suggest that BFOV prevents and improves dexamethasone-induced insulin resistance in 3T3-L1 adipocytes by enhancing expression of IRS-1 and GLUT4 mRNA.
authors.affiliation: Yunnan Pharmacological Laboratories of Natural Products, Kunming Medical College, Kunming, PR China.
authors.forename: Yi-Qing
authors.initials: YQ
authors.lastname: Zuo
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Liu
authors.forename: Yan-Fen
authors.initials: YF
authors.lastname: Niu
authors.forename: Chang-Fu
authors.initials: CF
authors.lastname: Tian
authors.forename: Ming-Jin
authors.initials: MJ
authors.lastname: Xie
authors.forename: Xi-Zhu
authors.initials: XZ
authors.lastname: Chen
authors.forename: Ling
authors.initials: L
authors.lastname: Li
mesh_terms: D041721:3T3-L1 Cells; D017667:Adipocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D003907:Dexamethasone / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005938:Glucocorticoids / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology; D051275:Glucose Transporter Type 4 / Q000235:genetics / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology*; D055504:Insulin Receptor Substrate Proteins / Q000235:genetics / Q000378:metabolism; D007333:Insulin Resistance; D051379:Mice; D009942:Organometallic Compounds / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology; D017968:Vanadium Compounds / Q000494:pharmacology
chemical_list: D005938:Glucocorticoids; D051275:Glucose Transporter Type 4; D007004:Hypoglycemic Agents; D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; C526295:Irs1 protein, mouse; D009942:Organometallic Compounds; D045162:Thiazolidinediones; D017968:Vanadium Compounds; C512927:bis(alpha-furancarboxylato)oxovanadium(IV); D000077154:Rosiglitazone; C034028:vanadyl sulfate; D003907:Dexamethasone; D005947:Glucose